Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, and is characterized by great heterogeneity. The use of rituximab in treatment regimens has increased the patient survival rate, but some patients experience poor efficacy. It thus remains necessary to find new prognostic indicators to screen high-risk patients and provide targeted treatment. In recent years, many studies have confirmed correlations between T cell subsets and prognosis in DLBCL patients. This article will review the effects of different T cells on the prognosis in DLBCL patients.